Login
Super Investors DEERFIELD MANAGEMENT COMPANY, L.P.
DM

DEERFIELD MANAGEMENT COMPANY, L.P.

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$6.47B
Positions
77
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (54 quarters reported)

$9.59B $1.87B
Q2 13 Q1 16 Q4 18 Q3 21 Q2 24 Q3 26

$2.12B in Q2 2013 → $6.47B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Revolution Medicines Inc 6.7% Trimmed 11% 2,124,000 $436M
BS Brookdale Sr Living Inc 6.6% Unchanged 306,885,000 $426M
CD Centene Corp Del 4.7% Unchanged 4,901,000 $304M
UT United Therapeutics Corp Del 4.5% Added 18% 540,598 $293M
PP Praxis Precision Medicines I 4.3% Unchanged 963,351 $281M
Revolution Medicines Inc 4.0% Unchanged 200,000,000 $258M
Genmab A/s 3.8% Unchanged 6,865,000 $245M
AP Arrowhead Pharmaceuticals In 3.2% Unchanged 200,000,000 $206M
Viatris Inc 3.0% Trimmed 46% 10,938,000 $194M
Cogent Biosciences Inc 3.0% Added 19% 5,957,000 $191M
Celcuity Inc 2.9% Added 65% 2,397,664 $191M
Legend Biotech Corp 2.5% Unchanged 8,137,638 $162M
VT Vera Therapeutics Inc 2.2% Added 11% 4,338,778 $140M
Tango Therapeutics Inc 2.0% Added 24% 5,180,000 $129M
Biocryst Pharmaceuticals Inc 2.0% Added 2.6% 15,490,928 $129M
BS Brookdale Sr Living Inc 1.9% Unchanged 11,637,032 $126M
Biomarin Pharmaceutical Inc 1.9% Added 52% 2,025,146 $122M
Ionis Pharmaceuticals Inc 1.8% Added 34% 2,660,669 $119M
Larimar Therapeutics Inc 1.8% Unchanged 35,606,974 $114M
NP Newamsterdam Pharma Company 1.6% Trimmed 0.2% 4,254,314 $103M
Mineralys Therapeutics Inc 1.5% Unchanged 3,958,000 $99.5M
Celcuity Inc 1.5% Unchanged 100,000,000 $96.5M
Boston Scientific Corp 1.4% Added 62% 2,135,440 $93.2M
CN Chemed Corp New 1.4% Added 507% 182,000 $91.9M
IM Inspire Med Sys Inc 1.4% Unchanged 1,296,862 $90M
Tempus Ai Inc 1.4% New 70,000,000 $88.2M
Zenas Biopharma Inc 1.3% Unchanged 67,200,000 $85.7M
BR Bio Rad Labs Inc 1.3% Unchanged 226,070 $85.4M
Pharvaris N V 1.3% Trimmed 23% 2,590,000 $82.2M
Dianthus Therapeutics Inc 1.2% Trimmed 19% 914,000 $80.5M
Ideaya Biosciences Inc 1.2% Trimmed 26% 2,003,000 $77M
Syndax Pharmaceuticals Inc 1.1% Unchanged 3,779,900 $71.1M
Savara Inc 1.1% Unchanged 13,569,000 $70M
Certara Inc 1.1% Unchanged 7,512,928 $69.1M
AH Acadia Healthcare Company In 1.1% Trimmed 45% 2,493,589 $68.6M
Ionis Pharmaceuticals Inc 1.0% Unchanged 60,000,000 $66M
Adapthealth Corp 1.0% Unchanged 11,477,730 $64.7M
Alignment Healthcare Inc 0.9% Unchanged 61,000,000 $61.1M
PM Parabilis Medicines Inc 0.9% Unchanged 1,880,704 $60.7M
Xenon Pharmaceuticals Inc 0.9% Unchanged 1,615,696 $60.1M
AP Arrowhead Pharmaceuticals In 0.9% Trimmed 39% 843,063 $55.2M
Envista Holdings Corporation 0.8% Unchanged 2,210,100 $51.9M
Stoke Therapeutics Inc 0.7% Unchanged 1,823,500 $47.4M
Zoetis Inc 0.7% New 632,000 $44.1M
Livanova PLC 0.7% Unchanged 34,280,000 $44M
Disc Medicine Inc 0.7% Unchanged 657,000 $43M
Beta Bionics Inc 0.6% Added 44% 1,903,710 $36.1M
Structure Therapeutics Inc 0.5% Unchanged 1,086,000 $34M
Ars Pharmaceuticals Inc 0.5% Unchanged 7,503,812 $32.3M
Belite Bio Inc 0.5% Trimmed 47% 190,000 $32.3M
CC Cooper Cos Inc 0.5% New 557,000 $31.5M
BT Blossomhill Therapeutics Inc 0.4% New 1,446,000 $27M
Odyssey Therapeutics Inc 0.4% Unchanged 1,046,139 $23.2M
Tandem Diabetes Care Inc 0.4% New 1,390,909 $22.7M
Starling Oncology Inc 0.3% Unchanged 3,360,052 $21.2M
AP Avalyn Pharmaceuticals Inc 0.3% Unchanged 731,000 $20.8M
Alamar Biosciences Inc 0.3% Unchanged 600,000 $20.4M
Tyra Biosciences Inc 0.2% Trimmed 28% 732,392 $16M
Foghorn Therapeutics Inc 0.2% Unchanged 4,394,367 $15.7M
V Vogenx Inc 0.2% New 635,707 $14.5M

Showing top 60 of 77 positions.

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Nuvalent Inc Exited −17,248,450 −$2.13B —
Viatris Inc Trimmed −9,268,170 −$164M 3.0%
Tempus Ai Inc New +70,000,000 +$88.2M 1.4%
LH Lantheus Hldgs Inc Exited −752,999 −$83.5M —
CN Chemed Corp New Added +152,000 +$76.8M 1.4%
Celcuity Inc Added +946,650 +$75.3M 2.9%
Pfizer Inc Exited −3,040,000 −$73.2M —
Indivior Pharmaceuticals Inc Exited −1,648,895 −$67.7M —
Caredx Inc Exited −1,997,618 −$56.9M —
AH Acadia Healthcare Company In Trimmed −2,026,411 −$55.7M 1.1%

Showing the 10 largest of 45 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Revolution Medicines Inc New +200,000,000 +$252M 2.6%
Mirum Pharmaceuticals Inc Exited −70,000,000 −$209M —
Cogent Biosciences Inc Trimmed −4,037,799 −$156M 2.0%
Genmab A/s Added +4,403,000 +$121M 2.0%
Celcuity Inc New +100,000,000 +$114M 1.2%
Mineralys Therapeutics Inc New +3,958,000 +$107M 1.1%
Catalyst Pharmaceuticals Inc Exited −3,943,600 −$97.6M —
Neurocrine Biosciences Inc Exited −610,000 −$80.4M —
DO Day One Biopharmaceuticals I Exited −3,723,131 −$79.8M —
Enhabit Inc Exited −4,747,746 −$66.9M —

Showing the 10 largest of 52 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
AP Arrowhead Pharmaceuticals In New +200,000,000 +$207M 2.4%
Indivior PLC Exited −3,393,063 −$122M —
Indivior Pharmaceuticals Inc New +3,097,790 +$94.4M 1.1%
Syndax Pharmaceuticals Inc New +3,779,900 +$88.3M 1.0%
Dianthus Therapeutics Inc New +1,019,813 +$85.6M 1.0%
Pfizer Inc New +3,040,000 +$85.4M 1.0%
Neurocrine Biosciences Inc Trimmed −574,345 −$75.7M 0.9%
Zenas Biopharma Inc New +65,000,000 +$67.3M 0.8%
Genmab A/s New +2,462,000 +$66.1M 0.8%
Xenon Pharmaceuticals Inc Added +1,073,676 +$62.4M 1.1%

Showing the 10 largest of 116 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
BS Brookdale Sr Living Inc New +306,885,000 +$427M 5.5%
Merus N V Exited −3,046,916 −$287M —
Indivior PLC Trimmed −3,593,748 −$129M 1.6%
CD Centene Corp Del Trimmed −2,598,002 −$107M 3.4%
Bristol-myers Squibb Co Exited −2,337,771 −$105M —
Celcuity Inc Added +980,470 +$97.8M 2.2%
Alignment Healthcare Inc New +61,000,000 +$92.6M 1.2%
Tandem Diabetes Care Inc Exited −100,000,000 −$87.1M —
Merck & Co Inc Exited −1,030,000 −$86.4M —
Pfizer Inc Exited −3,303,790 −$84.2M —

Showing the 10 largest of 147 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
Oscar Health Inc Exited −11,649,591 −$250M —
CD Centene Corp Del Added +5,860,630 +$209M 4.9%
IL Integra Lifesciences Hldgs C Exited −174,364,000 −$173M —
Alnylam Pharmaceuticals Inc Exited −110,000,000 −$143M —
Ionis Pharmaceuticals Inc New +1,979,669 +$130M 2.0%
Bristol-myers Squibb Co New +2,337,771 +$105M 1.6%
Cogent Biosciences Inc Added +6,412,903 +$92.1M 2.0%
Indivior PLC Trimmed −3,580,349 −$86.3M 2.6%
Ionis Pharmaceuticals Inc New +60,000,000 +$82.7M 1.3%
IM Inspire Med Sys Inc Added +907,694 +$67.4M 1.2%

Showing the 10 largest of 137 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Accolade Inc Exited −132,598,000 −$131M —
UT United Therapeutics Corp Del Added +265,400 +$76.3M 2.8%
Merck & Co Inc New +857,724 +$67.9M 1.2%
Dynavax Technologies Corp Exited −5,191,493 −$67.3M —
Alignment Healthcare Inc Trimmed −4,224,915 −$59.1M 0.1%
VT Vera Therapeutics Inc Added +2,298,117 +$54.1M 1.4%
Legend Biotech Corp Added +1,218,783 +$43.3M 1.9%
Neurocrine Biosciences Inc Trimmed −321,198 −$40.4M 2.7%
Tandem Diabetes Care Inc New +40,000,000 +$38.5M 0.7%
Chimerix Inc Exited −3,771,342 −$32.1M —

Showing the 10 largest of 130 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
WH Waystar Hldg Corp Exited −3,295,260 −$121M —
UT United Therapeutics Corp Del New +275,226 +$84.8M 1.7%
Pfizer Inc New +3,347,296 +$84.8M 1.7%
Neurocrine Biosciences Inc Added +627,000 +$69.3M 3.3%
O& Owens & Minor Inc New Exited −4,911,979 −$64.2M —
Alignment Healthcare Inc Trimmed −2,736,829 −$51M 1.7%
AH Alphatec Hldgs Inc Exited −49,500,000 −$46.7M —
Galapagos Nv Exited −1,411,000 −$38.8M —
Insmed Inc New +458,000 +$34.9M 0.7%
Bicara Therapeutics Inc Exited −1,795,174 −$31.3M —

Showing the 10 largest of 114 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Nuvalent Inc Trimmed −2,000,000 −$157M 26.7%
Kura Oncology Inc Exited −5,411,571 −$106M —
NP Newamsterdam Pharma Company Added +3,412,590 +$87.7M 2.1%
Dynavax Technologies Corp Added +5,172,263 +$66M 1.3%
Catalyst Pharmaceuticals Inc Trimmed −3,096,623 −$64.6M 1.2%
AH Alphatec Hldgs Inc Trimmed −68,000,000 −$64.2M 0.9%
Neurocrine Biosciences Inc Trimmed −454,590 −$62.1M 2.2%
WH Waystar Hldg Corp Trimmed −1,656,744 −$60.8M 2.3%
Surgery Partners Inc Exited −1,780,287 −$57.4M —
Cvs Health Corp Exited −874,800 −$55M —

Showing the 10 largest of 433 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support